No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
IART Integra Lifesciences
- 30.800
- +1.200+4.05%
Close May 30 16:00 ET
- 30.580
- -0.220-0.71%
Post 19:56 ET
2.43BMarket Cap60.39P/E (TTM)
30.940High29.330Low1.29MVolume29.640Open29.600Pre Close39.61MTurnover1.91%Turnover Ratio36.67P/E (Static)78.80MShares46.75052wk High1.52P/B2.08BFloat Cap22.36052wk Low--Dividend TTM67.60MShs Float77.400Historical High--Div YieldTTM5.44%Amplitude1.500Historical Low30.616Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
$1.5M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed mostly higher on Friday, there were a few notable insider trades.When insiders purchase shares, it indicates their confidence in the company's prospects or that they view t
What Does Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Share Price Indicate?
Integra Lifesciences(IART.US) Officer Buys US$1.5 Million in Common Stock
$Integra Lifesciences(IART.US)$ Officer ESSIG STUART purchased 52,641 shares of common stock on May 23, 2024 at an average price of $28.4945 for a total value of $1.5 million.Source: Announcement What
Integra Lifesciences Holdings Insider Bought Shares Worth $1,499,979, According to a Recent SEC Filing
Stuart Essig, Director, Executive Chairman of the Board, on May 23, 2024, executed a purchase for 52,641 shares in Integra Lifesciences Holdings (IART) for $1,499,979. Following the Form 4 filing with
Citi Maintains Integra Lifesciences(IART.US) With Hold Rating, Cuts Target Price to $28
Citi analyst Joanne Wuensch maintains $Integra Lifesciences(IART.US)$ with a hold rating, and adjusts the target price from $38 to $28.According to TipRanks data, the analyst has a success rate of 62.
Integra Lifesciences(IART.US) Director Buys US$995.82K in Common Stock
$Integra Lifesciences(IART.US)$ Director HILL BARBARA B purchased 36,350 shares of common stock on May 21, 2024 at an average price of $27.3952 for a total value of $995.82K.Source: Announcement What
Comments
EPS growth doesn't align with share price, indicating it may not reflect business performance or growth expectations may have been high. Integra LifeSciences Holdings' performance led to a 3% annual loss for shareholders over five years. Investors should note 3 warning signs.
While Shareholders of Integra LifeSciences Holdings (NASDAQ:IART) Are in the Red Over the Last Three Years, Underlying Earnings Have Actually GrownInsider transactions suggest a positive outlook for Integra LifeSciences Holdings, with insiders net buying the stock. The level of insider ownership indicates a reasonable degree of alignment with shareholder interests.
1
Integra LifeSciences Holdings trades at a low price, suggesting a buying opportunity. Higher cash flow is expected, potentially boosting share valuation. The positive outlook seems not fully factored into the share price, indicating it's not too late to buy IART.
Analysts insist that Integra LifeSciences' robust future growth justifies its high P/E, negating any expectations of a significant share price drop due to low odds of earnings deterioration.
The Acclarent acquisition provides Integra LifeSciences the chance to scale and seize leadership in the ENT device segment, enriching its innovative portfolio and providing shareholder value. In tandem with Integra's neurosurgery segment, it signifies a strategic move that will enhance innovation across ENT and other CSS technologies.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
